Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 13,940 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Rotator Cuff Tears
Interventions: Testosterone cypionate, Placebos; Drug
Lead sponsor: Orthopedic Institute, Sioux Falls, SD; Other
Eligibility: 45 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Well-Being, Psychological
Interventions: Conversational Agent Zenny, Web-based Wellness Resources; Behavioral
Lead sponsor: University of Klagenfurt; Other
Eligibility: 18 Years and older
Enrollment: 1,595 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: Female Dyspareunia
Interventions: Low intensity shockwave treatment to pelvic floor region plus typical physical therapy, Sham shockwave treatment plus typical physical therapy; Device
Lead sponsor: SoftWave Tissue Regeneration Technologies; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Endometrial Cancer
Interventions: Selinexor, Matching Placebo for selinexor; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 55 more

Conditions: Breast Cancer, Fatigue, Hypothyroidism
Interventions: physiologic testing, fatigue assessment and management, management of therapy complications; Other · Procedure
Lead sponsor: University of South Florida; Other
Eligibility: 20 Years to 80 Years · Female only
Enrollment: 541 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 41
States / cities: Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more

Conditions: PTSD, Post ICU Syndrome
Interventions: Diary (blank journal) plus PTSD psycho-education, PTSD psycho-education alone; Other
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Urinary Retention, Urinary Tract Infections
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Abdominal Aortic Aneurysm
Interventions: PEVAR (ProGlide closure), SEVAR (IntuiTrak), PEVAR (Prostar XL closure); Device
Lead sponsor: Endologix; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 20
States / cities: Loma Linda, California • San Diego, California • Fort Lauderdale, Florida + 15 more

Conditions: Premature Birth
Interventions: Arabin Pessary; Device
Lead sponsor: Gene Lee, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Kansas City, Kansas • Charleston, South Carolina

Conditions: Stress, Menopause, Fatigue, Sleep
Interventions: Radicle Revive Placebo Control Form 1, Radicle Revive Active Study Product 1; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 40 Years to 105 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Pediatric ALL, Cancer
Interventions: IPAD, Augmented Reality; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 5 Years to 15 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Hypertension, Pregnancy Induced
Interventions: High-touch blood pressure management, Low-touch blood pressure management; Other
Lead sponsor: Jennifer Lewey, MD, MPH; Other
Eligibility: 18 Years and older · Female only
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Heart Failure
Interventions: Sensor-controlled digital game (SCDG), Sensor Only; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 45 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Disease, Hodgkin
Interventions: brentuximab vedotin, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 32
States / cities: Duarte, California • San Francisco, California • Stanford, California + 26 more

Conditions: HIV Prevention, HCV, Opioid Use, Intravenous Drug Usage
Interventions: ARTAS Adapted Patient Navigation, Adherence Counseling; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 446 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Miami, Florida • New York, New York

Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Male only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • Newport Beach, California • Orange, California + 3 more

Conditions: Development, Infant
Interventions: Maternal Scent; Other
Lead sponsor: Columbia University; Other
Eligibility: 30 Weeks to 36 Weeks
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Uproleselan, Placebo, Melphalan; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dermatitis
Interventions: tacrolimus ointment, placebo ointment; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 17 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Kansas City, Kansas • Shawnee, Kansas + 7 more

Conditions: Plasma Cell Myeloma Refractory
Interventions: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Diabetic Retinopathy
Interventions: BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 40
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Frail Older Adults
Interventions: Progressive Multi-Component Intervention, Usual Care; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Glenside, Pennsylvania

Conditions: Infertility
Interventions: Follitropin delta, Placebo; Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more

Search by objective public record fields.

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

A Bot-based Self-help Program (WELL)

A Study of Participants Ages 21-65 Diagnosed With Dyspareunia and the Effects of Low Intensity Shockwave Treatment

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

Intensive Care Unit (ICU) Diary Project

Prevention of Post-operative Urinary Retention

Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial

Cervical Pessary to Prevent Preterm Birth in Singleton Pregnancies With a Sonographically Measured Short Cervix

Radicle Revive 24: A Study of Health and Wellness Products on Hormonal Health and Associated Health Outcomes in Women With Peri-Menopausal Health Issues

A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)

Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension

Sensor-controlled Digital Game for Heart Failure Self-management: A Clinical Trial

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Integrated HIV Prevention and HCV Care for PWID

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

The Effect of Maternal Scent on Sleep Wake States

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

Improving Function, Participation and Function After Acute Hospitalization in Older Adults

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)